Quarterly ResultAug 5, 2026, 07:22 AM
Rapport Therapeutics Q2 Net Loss $56.6M; RAP-219 Phase 3 Initiated
AI Summary
Rapport Therapeutics reported a net loss of $56.6 million for the second quarter of 2026, an increase from $26.7 million in the prior year, primarily due to higher R&D expenses of $51.4 million. Despite the increased loss, the company announced significant pipeline progress, including the initiation of its RAP-219 Phase 3 program for focal onset seizures and anticipated topline results in October 2026 for the RAP-219 Phase 2 trial in bipolar mania. Rapport ended the quarter with a strong cash position of $436.1 million, providing a cash runway into the second half of 2029.
Key Highlights
- Net Loss for Q2 2026 was $56.6 million, compared to $26.7 million in Q2 2025.
- Research and Development expenses increased to $51.4 million in Q2 2026.
- Selling, General and Administrative expenses were $9.4 million in Q2 2026.
- Ended Q2 2026 with $436.1 million in cash, cash equivalents, and short-term investments.
- Cash runway is expected to fund operations into the second half of 2029.
- RAP-219 Phase 3 program in focal onset seizures (FOS) initiated.
- RAP-219 Phase 2 trial in bipolar mania expects topline results in October 2026.
- RAP-219 half-life now estimated at 22 days, up from 14 days.
Price Impact
More from RAPP